Your browser doesn't support javascript.
loading
Unravelling the spectrum of von Willebrand factor variants in quantitative von Willebrand disease: results from a German cohort study.
Krahforst, Alexander; Yadegari, Hamideh; Pavlova, Anna; Pezeshkpoor, Behnaz; Müller, Jens; Pötzsch, Bernd; Scholz, Ute; Richter, Heinrich; Trobisch, Heiner; Liebscher, Karin; Olivieri, Martin; Trautmann-Grill, Karolin; Knöfler, Ralf; Halimeh, Susan; Oldenburg, Johannes.
  • Krahforst A; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Yadegari H; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany. Electronic address: hamideh.yadegari@ukbonn.de.
  • Pavlova A; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Pezeshkpoor B; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Müller J; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Pötzsch B; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Scholz U; Center of Hemostasis, Medizinisches Versorgungszentrum Labor Leipzig, Leipzig, Germany.
  • Richter H; Münster Hemostasis Center, Münster, Germany.
  • Trobisch H; Laboratory and Ambulance for Coagulation Disorders, Duisburg, Germany.
  • Liebscher K; Institute of Transfusion Medicine and Clinical Hemostaseology, Klinikum St. Georg GmbH, Leipzig, Germany.
  • Olivieri M; Pediatric Thrombosis and Hemostasis Unit, Dr Von Hauner Children's Hospital, LMU Klinikum, Munich, Germany.
  • Trautmann-Grill K; University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Knöfler R; Department of Pediatric Hemostaseology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Children's Hospital, Dresden, Sachsen, Germany.
  • Halimeh S; Coagulation Center Rhein-Ruhr, Duisburg, Germany.
  • Oldenburg J; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
J Thromb Haemost ; 2024 Jul 11.
Article en En | MEDLINE | ID: mdl-39002731
ABSTRACT

BACKGROUND:

Von Willebrand disease (VWD), the most prevalent hereditary bleeding disorder, results from deficiency of von Willebrand factor (VWF).

OBJECTIVES:

This large cohort study aims to offer a comprehensive exploration of mutation spectra and laboratory features in quantitative VWF deficiencies, shedding light on genetic underpinnings and genotype-phenotype associations.

METHODS:

Our cohort consisted of 221 Caucasian index patients with quantitative VWD, along with 47 individuals whose plasma VWF levels fell within the lower normal boundaries (50-70 IU/dL). We conducted comprehensive VWF assays and genetic analyses, encompassing VWF gene sequencing, copy number variation investigations, and bioinformatic assessments.

RESULTS:

Following International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee VWF guidelines, 77 index patients were characterized as having type 1 VWD (VWF antigen [VWFAg] < 30 IU/dL), 111 as having type 1 VWD (VWFAg, 30-50 IU/dL), and 33 as having type 3 VWD. Mutation detection rates were 88%, 65%, and 92%, respectively. Notably, blood group O overrepresentation was evident in type 1 with VWFAg of 30 to 50 IU/dL, particularly among mutation-negative patients, suggesting a potential causal role of blood group O. A total of 223 VWF variants, comprising 147 distinct variations, were identified in quantitative VWD patients, of which 57 were novel variants (39%). Additionally, approximately 70% of individuals with VWF levels within the lower normal boundaries (50-70 IU/dL) displayed VWF variants.

CONCLUSION:

Our data advance our understanding of the molecular mechanisms underlying quantitative VWD, offering valuable insights for future research and clinical management. Distinct mutation patterns were observed among subgroups, particularly the contrast between type 1 VWD (VWFAg < 30 IU/dL) and type 1 VWD (VWFAg, 30-50 IU/dL), an area with limited prior investigation.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article